Statute Details
- Title: Medicines (Good Manufacturing Practice Certificate) Regulations
- Act Code: MA1975-RG16
- Type: Subsidiary Legislation (SL)
- Authorising Act: Medicines Act (Chapter 176), Section 74
- Current Version: Current version as at 27 Mar 2026
- Key Provisions (Extract):
- Section 2: Definitions
- Section 4: Fees payable for a GMP Certificate
- Section 3: Application process for a GMP Certificate
- Legislative History (selected):
- SL 130/2002 (1 Jun 2002)
- 2004 RevEd (29 Feb 2004)
- S 30/2007 (1 Feb 2007)
- S 37/2013 (1 Feb 2013)
- S 99/2019 (2 Apr 2019)
- S 460/2022 (1 Jul 2022)
- S 491/2024 (1 Jul 2024)
What Is This Legislation About?
The Medicines (Good Manufacturing Practice Certificate) Regulations (“GMP Certificate Regulations”) set out the administrative framework for obtaining a Good Manufacturing Practice (“GMP”) Certificate in Singapore for the manufacture of medicinal products and active pharmaceutical ingredients (“APIs”). In plain terms, the Regulations provide the rules for how manufacturers apply to the licensing authority, how the authority assesses conformity with GMP standards, how long a certificate lasts, and what fees apply.
GMP is a quality assurance system designed to ensure that medicinal products and APIs are consistently produced and controlled to meet quality standards appropriate to their intended use. The Regulations do not themselves prescribe the detailed GMP requirements; instead, they define the relevant GMP standard and create a certification mechanism that ties manufacturing compliance to an official certificate.
Practically, the Regulations are important because GMP certification is typically a gatekeeping requirement for regulatory approval and ongoing market access. For manufacturers, the Regulations translate GMP compliance into a formal, time-limited credential issued by the licensing authority, subject to terms and conditions the authority considers fit.
What Are the Key Provisions?
1. Definitions and the GMP standard (Section 2)
Section 2 provides key definitions that anchor the certification regime. It defines an “active pharmaceutical ingredient” as any raw material used as an active ingredient in the manufacture of a medicinal product. It also defines a “Good Manufacturing Practice Certificate” (or “GMP Certificate”) as a certificate relating to the manufacture of a medicinal product or an API, attesting to conformity with a GMP Standard.
Most importantly, Section 2 defines the “Good Manufacturing Practice Standard” by reference to the Pharmaceutical Inspection Convention/Pharmaceutical Inspection Co-Operation Scheme (“PIC/S”) Guide to Good Manufacturing Practice for medicinal products or APIs (as applicable), or such other GMP standard approved by the licensing authority. This matters for practitioners because it clarifies that the certification is not based on an ad hoc or purely domestic standard; it is tied to internationally recognised GMP guidance, subject to possible approval of alternative standards by the regulator.
2. Application for a GMP Certificate (Section 3)
Section 3 governs how applications are made and how certificates are issued. Under Section 3(1), an application for a GMP Certificate must be made to the licensing authority “in such form and manner as the licensing authority may require,” for the purposes of Section 22 of the Medicines Act. This formulation is common in Singapore regulatory drafting: it gives the authority flexibility to specify application formats, supporting documents, and procedural steps.
Under Section 3(2), once an application is received, the licensing authority may issue a GMP Certificate to the manufacturer if it assesses satisfactory conformity with a GMP Standard. The authority may also impose “such terms and conditions as the licensing authority thinks fit.” For legal and compliance teams, this is a significant lever: even where GMP conformity is found, the certificate may still be issued subject to conditions that could affect operational requirements, reporting obligations, or limitations on scope.
3. Validity period and assessment timing (Section 3(3))
Section 3(3) sets the validity period of certificates, and it distinguishes between certificates issued before and after 1 February 2013. For certificates issued before 1 February 2013, validity is for a period not exceeding 2 years from the date of the certificate.
For certificates issued on or after 1 February 2013, validity is for a period not exceeding 3 years from the date the assessment (referred to in Section 3(2)) is completed. This change is subtle but important: it ties the expiry clock to the completion of the regulatory assessment rather than the certificate issuance date. In practice, this affects renewal planning, compliance calendar management, and the timing of re-assessments or inspections.
4. Fees and no-refund rule (Section 4)
Section 4 sets the fees payable for a GMP Certificate. Under Section 4(1), the fee is:
- $6,570 on application for a GMP Certificate; and
- $220 for each additional GMP Certificate that does not require further assessment of conformity with any GMP Standard.
These amounts were updated by amendments effective 1 July 2024 (S 491/2024), with earlier fee schedules amended by S 460/2022, S 99/2019, and S 30/2007. For practitioners advising on budgeting and cost recovery, it is essential to confirm the effective date of the fee schedule applicable to the application submission date.
Section 4(2) provides that no refund shall be made in respect of any fee paid under Section 4(1). This no-refund rule is a key risk allocation provision: even if an application is withdrawn, refused, or otherwise does not result in a certificate, the fee is not recoverable. Counsel should therefore ensure that clients conduct sufficient pre-submission readiness checks (e.g., gap assessments, documentation review, and mock inspections) to reduce the likelihood of unsuccessful applications.
How Is This Legislation Structured?
The Regulations are concise and structured around a small number of provisions. Based on the extract and the legislative listing, the instrument contains:
Section 1 (Citation) provides the short title.
Section 2 (Definitions) defines core terms, including “GMP Certificate,” “Good Manufacturing Practice Standard,” and “active pharmaceutical ingredient.”
Section 3 (Application for GMP Certificate) sets out the application mechanics, the licensing authority’s discretion to issue certificates upon satisfactory conformity, the ability to impose terms and conditions, and the certificate validity periods.
Section 4 (Fees) specifies the fee amounts and the no-refund rule.
Notably, the extract indicates “Parts: N/A,” reflecting that the Regulations are not divided into multiple Parts. Instead, they operate as a compact procedural and financial instrument supporting the Medicines Act’s broader GMP certification framework.
Who Does This Legislation Apply To?
The Regulations apply to manufacturers seeking a GMP Certificate for the manufacture of medicinal products or active pharmaceutical ingredients. The defined scope is broad enough to cover both finished dosage manufacturing and API production, provided the activity falls within the manufacturing of a medicinal product or API and the manufacturer is seeking certification under the Medicines Act framework.
In terms of procedural applicability, the Regulations govern the relationship between applicants and the licensing authority. While the licensing authority is not named in the extract, the Regulations clearly place the authority at the centre of assessment and issuance. For regulated entities, the practical implication is that compliance is assessed against the GMP Standard (PIC/S Guide or other approved standards), and the certificate’s terms and conditions are determined by the licensing authority.
Why Is This Legislation Important?
Although the GMP Certificate Regulations are short, they are operationally significant. They convert GMP compliance—often implemented through extensive quality systems—into a formal regulatory certificate with defined validity. This certificate can be a critical component of regulatory submissions and ongoing compliance posture, especially where market authorisation or product lifecycle requirements depend on verified manufacturing standards.
From a legal practitioner’s perspective, the most important practical points are: (i) the licensing authority’s discretion to issue certificates subject to terms and conditions; (ii) the validity period tied to assessment completion for post-2013 certificates; and (iii) the fee structure coupled with a strict no-refund rule. Each of these affects how counsel should structure advice on timelines, compliance readiness, and financial risk.
In enforcement and compliance terms, the Regulations also reinforce that GMP is assessed against an external standard (PIC/S Guide) or other approved GMP standards. This can influence how manufacturers interpret compliance expectations, particularly when international guidance is updated or when the licensing authority approves an alternative standard. Practitioners advising on audits, corrective and preventive actions (“CAPA”), and documentation should therefore align internal GMP systems with the relevant GMP Standard and anticipate that the licensing authority’s assessment will focus on conformity with that standard.
Related Legislation
- Medicines Act (Chapter 176) — in particular, Section 22 (referenced for the purpose of GMP Certificate applications) and Section 74 (authorising the making of these Regulations).
- PIC/S Guide to Good Manufacturing Practice (incorporated by reference as the “Good Manufacturing Practice Standard,” as applicable to medicinal products or APIs).
Source Documents
This article provides an overview of the Medicines (Good Manufacturing Practice Certificate) Regulations for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.